Related Experiment Video
Updated: Jul 28, 2025

In Vitro Method to Control Concentrations of Halogenated Gases in Cultured Alveolar Epithelial Cells
Published on: October 23, 2018
Sugammadex Is Associated With Reduced Pulmonary Complications in Patients With Respiratory Dysfunction
Yiqin Ji1, Hui Yuan2, Yijun Chen1
1Department of Anesthesiology, Ningbo First Hospital, Ningbo, Zhejiang, China.
Introduction:
Use of sugammadex is associated with fewer postoperative pulmonary complications (PPCs). This study investigated the relationship between sugammadex and PPCs in specific patients with respiratory dysfunction.
Materials And Methods:
We reviewed the electronic medical and anesthesia records of patients with respiratory dysfunction who underwent laparoscopic gastric or intestinal surgery at a single center between May 1, 2018 and December 31, 2019. The patients were divided into the sugammadex group and the nonsugammadex group, based on whether they received sugammadex or neostigmine. Binary logistic regression analyses were used to characterize the differences in incidence of PPC.
Results:
A total of 112 patients were included, of which 46 patients (41.1%) received sugammadex. In the logistic regression analysis, the incidences of PPC were fewer in the sugammadex group. Postoperative fever (odds ratio [OR] 0.330; 95% confidence interval [CI] 0.137-0.793, P = 0.0213), postoperative intensive care unit admission (OR 0.204; 95% CI 0.065-0.644, P = 0.007), cough (OR 0.143; 95% CI 0.061- 0.333, P < 0.001), pleural effusion (all) (OR: 0.280; 95% CI 0.104- 0.759, P = 0.012), pleural effusion (massive) (OR: 0.142; 95% CI 0.031- 0.653, P = 0.012), and difficulty in breathing (OR: 0.111; 95% CI 0.014-0.849, P = 0.039) showed significant differences between the two groups.
Conclusions:
Sugammadex is associated with a reduction in PPC in patients with respiratory dysfunction.
Insights
Sugammadex use in patients with respiratory dysfunction significantly reduced postoperative pulmonary complications (PPCs). This included fewer instances of fever, cough, and breathing difficulties, indicating improved patient outcomes.
Area of Science:
- Anesthesiology
- Pulmonology
- Surgical Outcomes
Background:
- Postoperative pulmonary complications (PPCs) are a significant concern in surgical patients.
- Sugammadex is a reversal agent for neuromuscular blockade, with potential benefits for respiratory function.
Conclusions:
- Sugammadex administration is linked to a reduction in postoperative pulmonary complications in patients with respiratory dysfunction.
- This suggests sugammadex may be a beneficial option for managing neuromuscular blockade reversal in this patient population.
More Related Videos
Related Concept Videos
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Skeletal Muscle Relaxants: Therapeutic Uses
Depolarizing Blockers: Pharmocokinetics
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Although all competitive neuromuscular blockers are designed...
Acute Respiratory Failure-III
Pulmonary Embolism III: Nursing Management

